BIOBIJOU Co., Ltd. Logo

BIOBIJOU Co., Ltd.

Develops and manufactures injectable aesthetic solutions like HA fillers for global markets.

489460 | KO

Overview

Corporate Details

ISIN(s):
KR7489460006
LEI:
Country:
South Korea
Address:
경기도 하남시 하남대로 947 에이동 1516호, 하남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BIOBIJOU Co., Ltd. is a global medical aesthetics company established in 2018. It specializes in the research, development, manufacturing, and sale of injectable products such as skin boosters, hyaluronic acid (HA) fillers, and fat-dissolving solutions, alongside other cosmetic items. The company manages an integrated value chain, from R&D and product design to production in its own GMP-certified facilities and global distribution. BIOBIJOU has established a robust sales network, exporting to over ten countries with a strong presence in the Chinese market. Through strategic R&D alliances and investment in high-level manufacturing, the company aims to deliver high-quality, competitively priced aesthetic solutions to the global market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 89.4 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.8 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.9 KB
2025-05-13 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 211.9 KB
2025-05-02 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 495.1 KB
2025-05-02 00:00
Prospectus
[기재정정]투자설명서
Korean 3.6 MB
2025-04-29 00:00
Prospectus
투자설명서
Korean 3.1 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.1 MB
2025-04-07 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.0 MB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]감사보고서 (2024.12)
Korean 493.5 KB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]연결감사보고서 (2024.12)
Korean 504.6 KB
2025-03-24 00:00
Registration Form
증권신고서(지분증권)
Korean 3.0 MB
2025-03-18 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 488.6 KB
2025-03-18 00:00
Audit Report / Information
연결감사보고서 (2024.12)
Korean 499.7 KB

Automate Your Workflow. Get a real-time feed of all BIOBIJOU Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOBIJOU Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOBIJOU Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Epitomee Medical Ltd. Logo
Develops ingestible therapeutic devices for weight management and targeted drug delivery.
Israel
EPIT
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.